A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Farasat KazmiShibani NicumRene L Roux Laura SpiersChat GnanaranjanAjithkumar SukumaranHani Gabra Essam GhazalyNigel W McCrackenDavid J HarrisonSarah P Blagden

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

NUC-1031 combined with carboplatin is well tolerated in recurrent ovarian cancer. Highest efficacy was observed at the RP2CD of 500 mg/m2 NUC-1031 on days 1 and 8 with AUC5 carboplatin day 1, every 3 weeks for six cycles. The ability to deliver carboplatin at AUC5 and the efficacy of this schedule even in patients with platinum-resistant disease makes this an attractive therapeutic combination.

Keyphrases

phase ii study
open label
phase iii
clinical trial
phase ii
locally advanced
study protocol
rectal cancer
gestational age
radiation therapy
preterm birth
double blind